Aadi Bioscience Inc AADI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AADI is a good fit for your portfolio.
News
-
Aadi Bioscience to Participate in the Jefferies Healthcare Conference
-
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting
-
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update
-
Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update
Trading Information
- Previous Close Price
- $1.61
- Day Range
- $1.58–1.67
- 52-Week Range
- $1.28–7.24
- Bid/Ask
- $1.56 / $1.63
- Market Cap
- $38.80 Mil
- Volume/Avg
- 139,132 / 218,691
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.79
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 75
- Website
- https://www.aadibio.com
Comparables
Valuation
|
Metric
|
AADI
|
CTIC
|
TYRA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.43 | — | 2.71 |
Price/Sales | 1.79 | 14.71 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
AADI
CTIC
TYRA
Financial Strength
|
Metric
|
AADI
|
CTIC
|
TYRA
|
|---|---|---|---|
Quick Ratio | 4.69 | 1.20 | 43.88 |
Current Ratio | 5.16 | 1.27 | 44.83 |
Interest Coverage | −323.04 | −3.20 | — |
Quick Ratio
AADI
CTIC
TYRA
Profitability
|
Metric
|
AADI
|
CTIC
|
TYRA
|
|---|---|---|---|
Return on Assets (Normalized) | −39.73% | −46.52% | −21.92% |
Return on Equity (Normalized) | −47.38% | — | −23.10% |
Return on Invested Capital (Normalized) | −51.68% | −143.40% | −27.33% |
Return on Assets
AADI
CTIC
TYRA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Kzxxgzmt | Rwcm | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Fjjdvxmf | Nbnjnf | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nymztqjl | Klndgc | $118.7 Bil | |||
| Moderna Inc
MRNA
| Mwxnjht | Lsypt | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vnmwvnh | Vcqbwl | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Xtgtcvy | Zsdw | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Mlrryzkx | Yjfb | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Kxyrctpw | Mrnwyr | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Jbgghxkk | Zxdsd | $15.0 Bil | |||
| Incyte Corp
INCY
| Pgwxsktp | Dkkqpd | $13.5 Bil |